Masimo Radius T from Masimo Corp. - wireless wearable for hospital telemetry
Masimo Radius T is a new wireless, wearable patient telemetry device designed for use in US hospitals. It allows continuous monitoring of vital signs like heart rate and respiration via Bluetooth and Wi-Fi, enabling patients to move freely without being tethered. This device aims to automate patient monitoring, reduce manual charting, and enhance flexibility in hospital wards, strengthening Masimo's position in the hospital automation market.
Masimo Corporation Actuals & Estimates (GETTEX:3M4)
This article provides an overview of Masimo Corporation's (GETTEX:3M4) financial actuals and estimates. It includes current stock price, ticker information, analyst forecasts, historical price data, volatility, market capitalization, and details on net income, EBITDA, and employee count. The article also touches upon investment advice and where to find more detailed financial reports and technical analysis.
Masimo Corporation Actuals & Estimates (BMV:MASI)
This article provides an overview of Masimo Corporation's (BMV:MASI) financial actuals and estimates, including its stock performance, analyst forecasts, and company fundamental data. It covers aspects like current stock price, market capitalization, earnings reports, and volatility, along with general investment disclaimers.
Enterprise value to EBITDA forward of Masimo Corporation – BMV:MASI
This article displays the "Enterprise value to EBITDA forward" for Masimo Corporation (BMV:MASI) on TradingView. It indicates that the company's market is currently closed with no trades. The article is primarily a display of financial data in chart format with a large amount of navigation and footer content.
Price to earnings forward of Masimo Corporation – BMV:MASI
This article provides financial information for Masimo Corporation (BMV:MASI), specifically focusing on its price to earnings forward. It indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial platform, showing the company's stock ticker and market details.
Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner
Masimo, a Danaher company, has received FDA 510(k) clearance for its new AI-enabled Opioid-Induced Respiratory Depression (OIRD) detection feature integrated into the Radius VSM® wearable continuous patient monitor. This advanced capability utilizes Masimo's smart SET™ pulse oximetry platform and pattern recognition to help clinicians identify early signs of respiratory compromise in patients on opioid therapy. The innovation aims to enhance patient safety by providing earlier insights and supporting more informed decisions in hospital settings.
Masimo wins FDA clearance for wearable opioid-risk monitor
Masimo, a Danaher company, has received FDA 510(k) clearance for its AI-enabled Opioid-Induced Respiratory Depression (OIRD) detection capability integrated into the Radius VSM® wearable continuous patient monitor. This new feature utilizes advanced pattern recognition with Masimo’s smart SET™ pulse oximetry sensor platform to help clinicians identify early signs of respiratory compromise in hospital patients on opioid therapy. The clearance aims to enhance patient safety by providing earlier insights and supporting faster clinical decisions.
[15-12G] MASIMO CORP SEC Filing
This SEC filing (Form 15-12G) indicates that Masimo Corporation (MASI) is terminating its registration under Section 12(g) of the Securities Exchange Act of 1934 and suspending its duty to file reports. This action follows Masimo's acquisition by Danaher Corporation, which was completed on June 10, 2026. As a result of the merger, Masimo is now a wholly owned subsidiary of Danaher.
Masimo Corp (MASI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Masimo Corp (MASI), detailing its regional revenue contributions. As of the latest update on April 6, the United States is the largest contributor, accounting for 62.65% of revenue, followed by Europe, Middle East and Africa. Data for business segments and future fiscal years (FY2024, FY2025) have not yet been disclosed by the company.
Masimo CEO stepping down following acquisition by Danaher
Masimo CEO Katie Szyman is stepping down from her role following the company's acquisition by Danaher. The article, published on June 15, 2026, details this leadership change after the recent acquisition.
Masimo (MASI) CEO awards canceled, paid $180 per share in Danaher deal
Masimo's CEO, Catherine M. Szyman, had all her equity awards and common stock canceled or converted as part of the company's merger with Danaher, which closed on June 10, 2026. Shareholders received $180.00 per share in cash for their common stock, while Szyman's unvested restricted stock units were converted into Danaher RSUs and outstanding options and performance-based RSUs were cashed out based on the merger price. This transaction resulted in Szyman holding no remaining Masimo equity.
Masimo (MASI) director’s shares and RSUs cashed out at $180 in Danaher merger
Masimo director Darlene J. S. Solomon reported the disposition of her Masimo common stock and Restricted Stock Units (RSUs) as part of the company's merger with Danaher Corporation. On June 10, 2026, all 3,015 shares and 1,119 RSUs were converted into a cash right of $180 per share. This transaction resulted in Solomon holding no Masimo common stock or RSUs post-merger.
Masimo (MASI) executive reports stock and RSU disposition in Danaher merger
An executive at Masimo (MASI), Paul Hataishi, reported the disposition of his common stock and Restricted Stock Units (RSUs) due to Masimo's merger with a Danaher subsidiary. All 13,317 of Hataishi's common shares were converted into $180.00 cash per share, and his unvested Masimo RSUs were assumed by Danaher and converted into Danaher RSUs based on specific merger terms. This transaction has resulted in Hataishi holding no direct Masimo common stock or RSUs post-merger.
Masimo (MASI) CFO exits company stock as Danaher cash merger closes
Masimo Corporation's CFO, Micah W. Young, disposed of all his Masimo equity interests on June 10, 2026, as the company merged into a wholly-owned subsidiary of Danaher Corporation. Each Masimo common share was converted into $180.00 cash, with outstanding performance-based restricted stock units also converted to cash at the same rate. Other restricted stock units were assumed by Danaher and converted into Danaher RSUs, reflecting a mechanical disposition due to the merger rather than an open-market trade.
Masimo (MASI) director’s shares and RSUs cashed out in Danaher merger
Masimo Corporation director Timothy J. Scannell reported the cash-out of his equity holdings, including 2,608 common shares and 1,119 restricted stock units (RSUs), as part of Masimo's merger with Danaher Corporation. Both common shares and RSUs were liquidated at $180.00 per share on June 10, 2026, leaving Scannell with no direct common stock holdings. This transaction was in accordance with the merger agreement, where Masimo became a wholly-owned subsidiary of Danaher.
[Form 4] MASIMO CORP Insider Trading Activity
A recent Form 4 filing reveals that Politan Capital Management's fund restructured its Masimo (MASI) exposure by terminating two forward sale contracts. These contracts, involving 142,681 and 130,869 MASI common shares, were initiated in March 2026 with upfront payments based on a $175.48/share trade price. Following a merger on June 10, 2026, the contracts were terminated, and Politan paid counterparties based on a $180.00/share price.
Politan Capital and Quentin Koffey cash out Masimo (MASI) at $180 per share
Insiders associated with Politan Capital, including Quentin Koffey, have fully divested their holdings in Masimo (MASI) following its merger with Danaher. On June 10, 2026, over 4.5 million common shares and 1,119 restricted stock units were converted into cash at a price of $180.00 per share. This transaction signifies the completion of the merger and shifts the investment focus to Danaher.
Masimo (MASI) director’s shares and RSUs cashed out in Danaher merger
Masimo Corporation's merger with Danaher Corporation closed on June 10, 2026, resulting in Masimo Director Michelle Brennan's equity being cashed out. She disposed of 9,309 common shares and had 1,119 restricted stock units canceled, all converted into a right to receive $180.00 per share. These transactions, directly with the issuer, mean Brennan holds no remaining Masimo shares or RSUs in this account.
Masimo (MASI) bought out for $180 per share as Politan exits stake
Masimo Corporation (MASI) completed its merger on June 10, 2026, with all common shareholders receiving $180.00 cash per share. Politan Capital Management, previously a major shareholder with 4,590,873 shares, and Quentin Koffey, with 1,119 restricted share units, have now fully exited their stakes, reporting 0 shares and 0.0% beneficial ownership. This SEC filing confirms the merger's closing and Masimo's transition to a wholly-owned subsidiary.
Masimo Corporation(NasdaqGS:MASI) dropped from S&P 400 Health Care
Masimo Corporation (NasdaqGS: MASI) has been dropped from the S&P 400 Health Care index, accompanied by several other S&P and NASDAQ composite index removals on June 9th and 10th. The medical technology company, known for its monitoring technologies and patient care solutions, has experienced these changes amidst broader revisions to various market indices. The article also provides a company profile and rating information.
MASIMO CORP SEC Filing
Masimo Corporation has filed a post-effective amendment to deregister all unsold securities previously registered on its Form S-3. This action follows the completion of its merger with Danaher Corporation on June 10, 2026, which resulted in Masimo becoming a wholly-owned subsidiary of Danaher. The filing terminates all offerings under the specified registration number, reflecting the administrative change after the corporate acquisition.
Masimo Received Notice of Delisting
Masimo (MASI) has received a notice of delisting from Nasdaq following its merger. Trading in its common stock ceased prior to market open on the closing date, and the company plans to file Form 15 to terminate its registration and suspend reporting obligations after Form 25 becomes effective.
[8-K] MASIMO CORP Reports Material Event
Danaher Corporation has completed its acquisition of Masimo Corporation for an all-cash consideration of $180.00 per share, making Masimo a wholly-owned subsidiary. As a result, Masimo's common stock ceased trading on Nasdaq, will be delisted and deregistered, and all prior stockholder rights have been terminated, other than the right to receive the cash merger consideration. The acquisition also led to the resignation of Masimo's pre-closing directors, and certain executives entered into separation and short-term consulting agreements while receiving change-in-control severance benefits.
Masimo Corporation stock hits 52-week high at 179.98 USD
Masimo Corporation stock has reached a 52-week high of $179.98, reflecting a 7.09% increase over the past year and significant surges in recent months. Despite trading slightly above its Fair Value according to InvestingPro, the company boasts strong financial health with a perfect Piotroski Score of 9. Recent analyst activity has focused on its acquisition by Danaher, leading to both a raised price target from Jefferies and a downgrade from Raymond James.
Discontinued operations of Masimo Corporation – XETR:3M4
This article briefly mentions the discontinued operations of Masimo Corporation, traded under the symbol XETR:3M4 on the Deutsche Borse Xetra. It appears to be a financial data page from TradingView, indicating a market status of "closed" with no trades. The main content focuses on financial information for the company.
Diluted shares outstanding of Masimo Corporation – XETR:3M4
This article provides financial data for Masimo Corporation (XETR:3M4), specifically focusing on its diluted shares outstanding. It notes that the market is closed with no trades and gives an overview of various financial data services and products offered by TradingView.
MASI Stock Price Prediction 2025-2026 | Masimo Corporation Forecast
24/7 Wall St. rates Masimo Corporation (MASI) as a "BUY" with a 12-month target price of $240.23, suggesting a 34.37% upside from its current price of $178.78. The analysis includes optimistic and conservative scenarios, projecting potential highs of $258.11 and lows of $202.16, respectively. The long-term forecast for 2030 anticipates an average price of $348.95, representing a potential 95.2% return.
Masimo Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Masimo misled investors about its sales pipeline and revenue guidance, causing a significant stock price drop on July 18, 2023, after lower-than-expected Q2 2023 earnings were announced. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the law firm.
Masimo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Masimo misled investors regarding its sales pipeline and revenue guidance, leading to a significant stock price drop after lower-than-expected Q2 2023 earnings were announced on July 17, 2023. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
Masimo Corporation (MASI) Stock Analysis: Navigating Growth in the Healthcare Sector with a Strong Return on Equity
Masimo Corporation (MASI) is a medical device giant in the healthcare sector, known for its innovative patient monitoring technologies, with a market capitalization of $9.36 billion. The company exhibits strong financial health with a 24.99% return on equity and 8.50% revenue growth, positioning it for long-term growth despite not paying dividends. Analyst ratings are cautiously optimistic, with an average target price suggesting a modest upside, and technical indicators reveal a stable trading scenario.
WATER ISLAND CAPITAL LLC's Masimo Corp(MASI) Holding History
WATER ISLAND CAPITAL LLC holds 194,197 shares of Masimo Corp (MASI), valued at $34.54 million, constituting 4.07% of its portfolio. The initial purchase was in Q1 2026 at an average price of $156.95 per share. Based on the current price of $178.81, the firm has an estimated gain of $4.25 million, or 13.93%.
Pentwater discloses 3.18M-share stake in Masimo (MASI)
Pentwater Capital Management LP has disclosed a beneficial ownership of 3,176,000 shares in Masimo Corp. (MASI), representing a 6.1% stake in the company. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The filing specifies that Pentwater Capital Management LP and Matthew Halbower, the sole shareholder of the investment manager's general partner, share both voting and dispositive power over these shares.
[SCHEDULE 13G] MASIMO CORP Passive Investment Disclosure (>5%)
Barclays PLC has filed a Schedule 13G for Masimo Corp (MASI), reporting beneficial ownership of 2,892,262 shares, which represents 5.54% of the common stock as of March 31, 2026. The filing indicates that Barclays PLC holds sole voting and dispositive power over these shares and lists several Barclays subsidiaries as relevant entities. The purpose of the investment is passive, with no intention to change or influence the control of the issuer.
Joe Kiani holds 3.66M shares of Masimo (NASDAQ: MASI), cites disputed awards
Joe Kiani reports beneficial ownership of 3.66 million shares (6.5%) of Masimo Corporation (NASDAQ: MASI), a figure that includes several disputed equity awards. Kiani contends that Masimo has refused to process certain exercises and issue shares related to these awards, leading to litigation in the Delaware Court of Chancery. His beneficial ownership calculation, based on 52,365,808 shares outstanding as of April 4, 2026, explicitly includes these contested awards for transparency, despite them not yet being issued by the company.
Swedbank AB Sells 8,000 Shares of Masimo Corporation $MASI
Swedbank AB has reduced its stake in Masimo Corporation by selling 8,000 shares, bringing its total holding to 59,500 shares valued at approximately $7.74 million. Despite increased institutional investment from several other firms, analyst sentiment for Masimo remains cautious, with an average "Hold" rating and a target price of $180.40 following recent downgrades. Masimo (NASDAQ:MASI) stock opened at $178.31, with a market capitalization of $9.34 billion.
MASI Price Today: Masimo Corporation Stock Price, Quote & Chart | MEXC
This article provides current stock information for Masimo Corporation (MASI), trading at $178.28 with a -0.11% change from its previous close. It details key market data, recent price movements over various periods, and how to buy MASI stock on MEXC. The report also includes company information, sector classification, market valuation, P/E ratio, and answers frequently asked questions about its financial performance and dividend policy.
Comerica Bank Lowers Stock Holdings in Masimo Corporation $MASI
Comerica Bank significantly reduced its stake in Masimo Corporation (NASDAQ:MASI) by 94.8% in the fourth quarter, selling over 221,000 shares. Despite this reduction, several other major institutional investors, including Viking Global and UBS Group AG, increased their positions, with institutional ownership of Masimo standing at approximately 85.96%. Masimo currently trades around $178.50, has a market cap of $9.35 billion, and analysts generally have a "Hold" rating with a consensus target price of $180.40.
Masimo Shareholder Notice
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Masimo misled investors about its sales pipeline and revenue guidance for fiscal 2023, leading to a significant stock price drop following their Q2 2023 earnings announcement. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
Wilson Asset Management International PTY Ltd. Increases Stock Position in Masimo Corporation $MASI
Wilson Asset Management International PTY Ltd. significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 44.8% in the fourth quarter, bringing its total holding to 39,437 shares valued at approximately $5.13 million. Despite substantial institutional ownership at 85.96%, analyst sentiment for Masimo remains cautious, with a "Reduce" consensus rating and a target price of $181.17, as the stock trades near its one-year high. Masimo, a medical technology company specializing in noninvasive monitoring solutions, has a market cap of $9.32 billion.
Masimo Corp 1Q 2026: Revenue $403.6M, Net income $57.1M, EPS $1.09— 10-Q Summary
Masimo Corp reported strong first-quarter 2026 results, with revenue increasing by 8.5% to $403.6 million and a significant turnaround in net income, reaching $57.1 million compared to a loss in the prior year. Diluted EPS rose to $1.09. The growth was primarily driven by higher consumables and service sales, along with strategic developments including the sale of its non-healthcare Sound United business and a merger agreement with Danaher.
Masimo (MASI) CHRO nets RSU shares after tax-withholding share disposition
Masimo's Chief Human Resources Officer, Elisabeth A. Hellmann, reported the vesting of 335 restricted stock units (RSUs) on April 21, 2026. In connection with this, 121 shares were withheld by the company for tax obligations at $178.43 per share. Following these routine transactions, Hellmann now holds 214 shares of common stock and 1,005 remaining RSUs.
Masimo (MASI) chair exercises 1,225 RSUs and receives 1,119-unit grant
Masimo Corp's Chairman of the Board, Michelle Brennan, reported recent equity compensation activity. She exercised 1,225 restricted stock units (RSUs) into common shares, increasing her direct holdings to 8,543 shares. Additionally, Brennan received a new grant of 1,119 RSUs, which will vest on the earlier of one year from the grant date or the next annual stockholders meeting.
Vanguard Group Inc. Sells 461,225 Shares of Masimo Corporation $MASI
Vanguard Group Inc. reduced its stake in Masimo Corporation (NASDAQ:MASI) by 9.6% in the fourth quarter, selling 461,225 shares. Despite this, Vanguard remains a significant shareholder, owning 4,348,786 shares valued at $565.6 million. Other institutional investors have shown mixed activity, with some increasing and others decreasing their holdings in the medical equipment provider.
Masimo Corporation $MASI Shares Purchased by UBS Group AG
UBS Group AG significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 252.9% in the fourth quarter, acquiring an additional 429,474 shares to own a total of 599,274 shares worth $77.94 million. Other institutional investors like Royal Bank of Canada and AQR Capital Management LLC also increased their positions. Despite these purchases, Wall Street analysts have issued a mixed outlook, with an average rating of "Reduce" and a consensus target price of $181.17, although some have maintained or raised their ratings.
BlackRock (MASI) holds 116,871 shares of Masimo — 0.2% stake
BlackRock Portfolio Management LLC has reported a passive beneficial ownership of 116,871 shares in Masimo Corp (MASI), representing a 0.2% stake. This information is detailed in an amended Schedule 13G/A filing dated April 30, 2026, which indicates BlackRock holds sole voting power over 94,486 shares and sole dispositive power over all 116,871 shares. This filing is considered a routine institutional report due to the stake being below 5%.
M&T Bank Corp Purchases 6,578 Shares of Masimo Corporation $MASI
M&T Bank Corp significantly increased its stake in Masimo Corporation by 218.8% in Q4, acquiring an additional 6,578 shares to hold a total of 9,585 shares valued at approximately $1.247 million. This move is part of a broader trend of institutional investors raising their positions in Masimo, with institutional ownership currently at 85.96%. Despite strong institutional interest, analysts largely maintain a "Hold" or "Reduce" rating on the stock, with a consensus target price of $181.17.
Masimo (MASI) Study Shows High Accuracy of Pulse Oximetry in Neo
A recent study by Masimo (MASI) published results highlighting the high accuracy and reliability of its SET pulse oximetry technology for critically ill newborns, demonstrating strong performance across diverse populations without discrepancies based on skin pigmentation. Despite the positive technological advancements, the company's stock shows a high valuation with a P/S ratio of 6.33 and recent insider selling, which investors should consider alongside its strong GF Score™ of 87/100. The study reinforces Masimo's leadership in healthcare technology, but financial metrics and insider sentiment warrant careful research.
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study – Company Announcement - FT.com
A new study, NeoPODS, confirmed the accuracy of Masimo SET® pulse oximetry in hospitalized newborns across all skin tones, showing less than 1% overall statistical bias and no clinically significant skin pigmentation-related discrepancies. The NIH-funded study found no occult hypoxemia in Black or Hispanic neonates, reinforcing the device's equitable performance in critical care settings. This research adds to existing evidence supporting Masimo SET®'s reliability under challenging real-world conditions for diverse patient populations.
Delaware Applies Moelis Amendment to Enforce Forum Selection in Stockholder Employment Agreement over Corporation’s Bylaw
The Delaware Court of Chancery recently ruled that a non-Delaware forum selection clause in a CEO's employment agreement superseded the corporation's bylaw mandating litigation in Delaware, even for fiduciary duty claims. This decision, based on the Moelis Amendment (8 Del. C. § 122(18)), has significant implications for Delaware corporations, particularly those with stockholder executives, as it validates non-Delaware forums for internal affairs disputes when established via stockholder agreements. Corporations are advised to review their existing agreements to avoid inadvertently overriding Delaware-only forum selection bylaws and consider internal affairs carveouts in future contracts.
Masimo (MASI) Proxy Filing Summary
Masimo's Board has unanimously approved an acquisition by Danaher for $180 per share, with the transaction expected to close in the second half of 2026. Masimo will operate as a standalone unit within Danaher's Diagnostics segment. Shareholders will vote on the proposed all-cash merger and related executive compensation at a forthcoming meeting.
